Castle Biosciences (CSTL) Projected to Post Quarterly Earnings on Monday

Castle Biosciences (NASDAQ:CSTL) will likely be issuing its Q2 2025 quarterly earnings data after the market closes on Monday, August 4th. Analysts expect the company to announce earnings of ($0.44) per share and revenue of $71.53 million for the quarter. Castle Biosciences has set its FY 2025 guidance at EPS.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.12). Castle Biosciences had a positive return on equity of 3.41% and a negative net margin of 1.46%. The firm had revenue of $87.99 million for the quarter, compared to analysts’ expectations of $80.40 million. On average, analysts expect Castle Biosciences to post $0 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Castle Biosciences Stock Down 3.3%

Shares of CSTL opened at $14.65 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 9.19 and a current ratio of 9.37. Castle Biosciences has a one year low of $14.61 and a one year high of $35.84. The stock has a market capitalization of $422.95 million, a price-to-earnings ratio of -77.11 and a beta of 1.09. The stock has a 50 day moving average price of $18.01 and a 200 day moving average price of $20.55.

Hedge Funds Weigh In On Castle Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CSTL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Castle Biosciences by 4.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,441 shares of the company’s stock valued at $309,000 after purchasing an additional 655 shares during the last quarter. Jones Financial Companies Lllp lifted its stake in shares of Castle Biosciences by 10,592.0% in the 1st quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock valued at $54,000 after purchasing an additional 2,648 shares during the last quarter. Amundi lifted its stake in shares of Castle Biosciences by 15,811.5% in the 1st quarter. Amundi now owns 4,137 shares of the company’s stock valued at $79,000 after purchasing an additional 4,111 shares during the last quarter. Finally, AQR Capital Management LLC lifted its stake in shares of Castle Biosciences by 548.9% in the 1st quarter. AQR Capital Management LLC now owns 137,022 shares of the company’s stock valued at $2,743,000 after purchasing an additional 115,907 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

CSTL has been the subject of several research reports. Canaccord Genuity Group dropped their price target on Castle Biosciences from $42.00 to $37.00 and set a “buy” rating for the company in a research report on Tuesday, May 6th. Scotiabank dropped their price target on Castle Biosciences from $44.00 to $40.00 and set a “sector outperform” rating for the company in a research report on Wednesday, May 21st. Finally, Lake Street Capital lowered their price objective on Castle Biosciences from $40.00 to $35.00 and set a “buy” rating on the stock in a research note on Tuesday, May 6th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $37.00.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.